Literature DB >> 20385853

Intravenous voriconazole after toxic oral administration.

J W C Alffenaar1, S van Assen, J G R de Monchy, D R A Uges, J G W Kosterink, T S van der Werf.   

Abstract

In a male patient with rhinocerebral invasive aspergillosis, prolonged high-dosage oral administration of voriconazole led to hepatotoxicity combined with a severe cutaneous reaction while intravenous administration in the same patient did not. High concentrations in the portal blood precipitate liver enzyme abnormalities, and therefore, oral administration of voriconazole may have a hepatotoxicity profile different from that of intravenous (i.v.) administration. Intravenously administered voriconazole might still be an option after oral-voriconazole-induced toxicity has resolved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385853      PMCID: PMC2876380          DOI: 10.1128/AAC.01193-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.

Authors:  Mark-David Levin; Jan G den Hollander; Bronno van der Holt; Bart J Rijnders; Martin van Vliet; Pieter Sonneveld; Ron H N van Schaik
Journal:  J Antimicrob Chemother       Date:  2007-09-07       Impact factor: 5.790

3.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

4.  Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

Authors:  Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis
Journal:  J Allergy Clin Immunol       Date:  2008-05-27       Impact factor: 10.793

5.  Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.

Authors:  Jan G den Hollander; Cornelis van Arkel; Bart J Rijnders; Pieternella J Lugtenburg; Siem de Marie; Mark-David Levin
Journal:  J Antimicrob Chemother       Date:  2006-03-23       Impact factor: 5.790

Review 6.  Therapeutic drug monitoring of voriconazole.

Authors:  Roger J M Brüggemann; J Peter Donnelly; Rob E Aarnoutse; Adilia Warris; Nicole M A Blijlevens; Johan W Mouton; Paul E Verweij; David M Burger
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

7.  Photoinduced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization.

Authors:  C F Chignell; A G Motten; G R Buettner
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

  7 in total
  1 in total

1.  Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis.

Authors:  Randa S Haddad; Georges M El-Mollayess
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.